Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs
– Multiple Phase 2 studies of allosteric TYK2 inhibitor in 2021 and 2022 will investigate ‘pipeline-in-a-product’ potential –
– Financing will also support first-in-human trial of HPK1 inhibitor and advancement of preclinical pipeline –
– Led by BVF Partners L.P., round included participation from new and existing investors –
CAMBRIDGE, Mass. – July 13, 2021 – Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the closing of a $105 million private financing round. The round was led by BVF Partners L.P. (BVF), with participation from existing investors including RA Capital Management and Atlas Venture. Access Biotechnology, Commodore Capital, Logos Capital, Surveyor Capital (a Citadel company), and a large alternative asset manager joined as new investors in this financing.
“This financing from some of the world’s leading investors is validation of the exciting potential within Nimbus’ product pipeline and the singular expertise Nimbus brings in advancing these products forward. Spurred by compelling data from studies of our novel allosteric TYK2 inhibitor, we will be embarking upon multiple Phase 2 clinical studies in 2021 and 2022 to elucidate the full range of potential patient benefit from this novel therapeutic,” said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. “Our clinical expertise with this molecule to date combined with our strong capital position make Nimbus uniquely well-resourced to advance this important medicine through the clinic in the years to come.”
In addition to the Phase 2 studies of Nimbus’ allosteric TYK2 inhibitor, the financing will support a first-in-human study of the company’s HPK1 inhibitor candidate in cancer patients with solid tumors, which will begin later this year, and will accelerate preclinical programs against multiple targets in oncology and immunology. The company expects to initiate IND-enabling studies on two novel agents in 2022.
“Nimbus’ pipeline is positioned to deliver multiple clinical readouts over the next 18 months that have the promise to help transform patients’ lives,” said Bruce Booth, D.Phil., co-founder and Chairman of the Board of Nimbus. “We are fortunate to have the support of many new investors joining Nimbus, and we welcome Sam Huang from BVF to the Board.”
“We’re proud to lead this most recent financing round, and we see the tremendous potential of Nimbus’ vision, pipeline, and team,” said Mark Lampert, founder and CEO of BVF.
About Nimbus Therapeutics
Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. www.nimbustx.com
Lisa Raffensperger, (617) 903-8783
Ten Bridge Communications